Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2023, Vol. 55 ›› Issue (3): 456-464. doi: 10.19723/j.issn.1671-167X.2023.03.011

Previous Articles     Next Articles

Metformin use and risk of ischemic stroke in patients with type 2 diabetes: A cohort study

Huan YU,Ruo-tong YANG,Si-yue WANG,Jun-hui WU,Meng-ying WANG,Xue-ying QIN,Tao WU,Da-fang CHEN,Yi-qun WU*(),Yong-hua HU   

  1. Department of Epidemiology and Biostatistics, Peking University School of Public Health; Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing 100191, China
  • Received:2023-02-28 Online:2023-06-18 Published:2023-06-12
  • Contact: Yi-qun WU E-mail:qywu118@163.com
  • Supported by:
    the National Natural Science Foundation of China(81703291)

RICH HTML

 15   

PDF (PC)

179

Abstract:

Objective: To explore the association between the use of metformin and the risk of ischemic stroke in patients with type 2 diabetes. Methods: A prospective cohort study was designed from the Fangshan family cohort in Beijing. According to metformin use at baseline, 2 625 patients with type 2 diabetes in Fangshan, Beijing were divided into metformin group or non-metformin group and the incidence of ischemic stroke between the different groups during follow-up was estimated and compared by Cox proportional hazard regression model. The participants with metformin were first compared with all the parti-cipants who did not use metformin, and then were further compared with those who did not use hypoglycemic agents and those who used other hypoglycemic agents. Results: The patients with type 2 diabetes were with an average age of (59.5±8.7) years, and 41.9% of them were male. The median follow-up time was 4.5 years. A total of 84 patients developed ischemic stroke during follow-up, with a crude incidence of 6.4 (95%CI: 5.0-7.7) per 1 000 person-years. Among all the participants, 1 149 (43.8%) took metformin, 1 476 (56.2%) were metformin non-users, including 593 (22.6%) used other hypoglycemic agents, and 883 (33.6%) did not use any hypoglycemic agents. Compared with metformin non-users, the Hazard ratio (HR) for ischemic stroke in metformin users was 0.58 (95%CI: 0.36-0.93; P = 0.024). Compared with other hypoglycemic agents, HR was 0.48 (95%CI: 0.28-0.84; P < 0.01); Compared with the group without hypoglycemic agents, HR was 0.65 (95%CI: 0.37-1.13; P=0.13). The association between metformin and ischemic stroke was statistically significant in the patients ≥ 60 years old compared with all the metformin non-users and those who used other hypoglycemic agents (HR: 0.48, 95%CI: 0.25-0.92; P < 0.05). Metformin use was associated with a lower incidence of ischemic stroke in the patients with good glycemic control (0.32, 95%CI: 0.13-0.77; P < 0.05). In the patients with poor glycemic control, and the association was not statistically significant (HR: 0.97, 95%CI: 0.53-1.79; P>0.05). There was an interaction between glycemic control and metformin use on incidence of ischemic stroke (Pinteraction < 0.05). The results of the sensitivity analysis were consistent with the results in the main analysis. Conclusion: Among patients with type 2 diabetic in rural areas of northern China, metformin use was associated with lower incidence of ischemic stroke, especially in patients older than 60 years. There was an interaction between glycemic control and metformin use in the incidence of ischemic stroke.

Key words: Cohort study, Metformin, Ischemic stroke, Type 2 diabetes

CLC Number: 

  • R186.4

Table 1

Basic characteristics of participants"

Characteristics Met users (n=1 149) Non-Met users (n =1 476) Overall (n =2 625) P
Age/years, $\bar x \pm s$ 59.6 ± 8.2 59.3 ± 9.0 59.5 ± 8.7 0.41
Gender, n (%) < 0.01
  Male 419 (36.5) 681 (46.1) 1 100 (41.9)
  Female 730 (63.5) 795 (53.9) 1 525 (58.1)
Marriage, n (%) 0.05
  Married 988 (86.0) 1 285 (87.1) 2 273 (86.6)
  Unmarried 160 (13.9) 182 (12.3) 342 (13.0)
AHI/thousands yuan，M(P25, P75) 12.0 (5.0, 36.0) 14.0 (7.2, 36.0) 12.8 (6.0, 36.0) 0.06
BMI/(kg/m2)，$\bar x \pm s$ 26.5 ± 3.6 26.6 ± 6.0 26.5 ± 5.1 0.54
Obesity, n (%) 0.83
  Yes 345 (30.0) 449 (30.4) 794 (30.3)
  No 859 (70.0) 1 027 (69.6) 1 831 (69.8)
Smoking, n (%) 0.04
  Current/past smoker 442 (38.5) 624 (42.3) 1 556 (59.3)
  Never 707 (61.5) 849 (57.5) 1 066 (40.6)
Drinking, n (%) 0.32
  Current/past drinker 342 (29.8) 464 (31.4) 1 813 (69.1)
  Never 807 (70.2) 1 006 (68.2) 806 (30.7)
Habitual sports, n (%) < 0.01
  Yes 632 (55.0) 546 (37.0) 1 178 (44.9)
  No 517 (45.0) 930 (63.0) 1 447 (55.1)
Comorbidity, n (%)
  Hyperlipidemia 1 003 (87.3) 1 319 (89.4) 2 322 (88.5) 0.10
  Hypertension 487 (42.4) 727 (49.3) 1 214 (46.3) < 0.01
Family history of IS, n (%) < 0.01
  Yes 539 (46.9) 887 (60.1) 1 426 (54.3)
  No 610 (53.1) 589 (39.9) 1 199 (45.7)

Table 2

Incidence of ischemic stroke in the participants"

Groups Events of IS, n Median follow-up time/years, M(P25, P75) Overall follow-up time/person-years Crude incidence rate/per 1 000 person-years, M(P25, P75)
Met users 25 4.4 (3.5, 6.4) 5 604.0 4.5 (2.7, 6.2)
Non-Met users 59 5.3 (4.2, 6.4) 7 574.0 7.8 (5.8, 9.8)
  OHA 27 4.5 (3.5, 6.4) 2 924.4 9.2 (5.8, 12.7)
  NHA 32 5.4 (4.4, 6.5) 4 649.6 6.9 (4.5, 9.3)

Table 3

Association of metformin use with ischemic stroke"

Groups Events of IS, n Adjusted incidence rate/per 1 000 person-years (95%CI) HR (95%CI) P
Overall
  Non-Met users 59 7.7 (6.1-9.4) -
  Met users 25 4.5 (3.6-5.5) 0.58 (0.36-0.93) 0.02
Male
  Non-Met users 27 7.7 (6.0-9.3) -
  Met Users 8 4.1 (3.2-4.9) 0.52 (0.23-1.17) 0.11
Female
  Non-Met users 32 7.7 (6.1-9.4) -
  Met Users 17 4.8 (3.8-5.8) 0.61 (0.33-1.12) 0.11
   < 60 years old
  Non-Met users 22 7.0 (5.5-8.4) -
  Met Users 12 5.5 (4.3-6.7) 0.79 (0.38-1.63) 0.52
  ≥60 years old
  Non-Met users 37 8.1 (6.4-9.8) -
  Met Users 13 4.0 (3.1-4.8) 0.48 (0.25-0.92) 0.03

Table 4

Association of metformin use with ischemic stroke referenced to different control groups"

CharacteristicsCompared with OHA group Compared with NHA group
Events of IS, n HR (95%CI) P Events of IS, n HR (95%CI) P
Overall 52 0.48 (0.28-0.84) < 0.01 57 0.65 (0.37-1.13) 0.13
Age/years
   < 60 21 0.69 (0.29-1.67) 0.41 25 1.00 (0.42-2.35) 1.00
  ≥60 31 0.39 (0.19-0.83) 0.01 32 0.48 (023-1.00) 0.05
Gender
  Female 29 0.56 (0.26-1.20) 0.13 37 0.59 (0.29-1.18) 0.13
  Male 23 0.39 (0.16-0.95) 0.04 20 0.78 (0.30-2.00) 0.60

Table 5

Interaction between glycemic control and metformin use on the risk of ischemic stroke"

Glycemic control HR (95%CI) P Pinteraction
Met users vs. Non-Met users 0.01
  Under control 0.32 (0.13-0.77) < 0.01
  Lose control 0.97 (0.53-1.79) 0.92
Met users vs. OHA 0.03
  Under control 0.28 (0.10-0.77) 0.01
  Lose control 0.69 (0.34-1.37) 0.29
Met users vs. NHA < 0.01
  Under control 0.34 (0.13-0.87) 0.02
  Lose control 1.27 (0.57-2.85) 0.56
1 Zhou M , Wang H , Zeng X , et al.Mortality, morbidity, and risk factors in China and its provinces, 1990—2017: A systematic analysis for the Global Burden of Disease Study 2017[J].Lancet,2019,394(10204):1145-1158.
doi: 10.1016/S0140-6736(19)30427-1
2 Wang YJ , Li ZX , Gu HQ , et al.China stroke statistics: An update on the 2019 report from the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, the Chinese Stroke Association, National Center for Chronic and Non-communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Institute for Global Neuroscience and Stroke Collaborations[J].Stroke Vasc Neurol,2022,7(5):415-450.
doi: 10.1136/svn-2021-001374
3 Ma Q , L iR , Wang L , et al.Temporal trend and attributable risk factors of stroke burden in China, 1990—2019: An analysis for the Global Burden of Disease Study 2019[J].Lancet Public health,2021,6(12):e897-e906.
doi: 10.1016/S2468-2667(21)00228-0
4 Van STT , Sedaghat S , Carnethon MR , et al.Cerebral microvascular complications of type 2 diabetes: Stroke, cognitive dysfunction, and depression[J].Lancet Diabetes Endocrinol,2020,8(4):325-336.
doi: 10.1016/S2213-8587(19)30405-X
5 Sarwar N , Gao P , Swshasai SR , et al.Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies[J].Lancet,2010,375(9733):2215-2222.
doi: 10.1016/S0140-6736(10)60484-9
6 韩荣荣, 唐爱奇, 方杭燕, 等.2型糖尿病患者并发脑卒中的前瞻性研究[J].预防医学,2017,29(2):139-141.
doi: 10.3969/j.issn.1673-758X.2017.02.014
7 Wang L , Gao P , Zhang M , et al.Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013[J].JAMA,2017,317(24):2515-2523.
doi: 10.1001/jama.2017.7596
8 Wang L , Peng W , Zhao Z , et al.Prevalence and treatment of diabetes in China, 2013—2018[J].JAMA,2021,326(24):2498-2506.
doi: 10.1001/jama.2021.22208
9 Ma RCW .Epidemiology of diabetes and diabetic complications in China[J].Diabetologia,2018,61(6):1249-1260.
doi: 10.1007/s00125-018-4557-7
10 Inzucchi SE , Bergenstal RM , Buse JB , et al.Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes[J].Diabetes Care,2015,38(1):140-149.
doi: 10.2337/dc14-2441
11 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)[J].中华糖尿病杂志,2021,13(4):95.
12 Oliveira WH , Nunes AK , França ME , et al.Effects of metformin on inflammation and short-term memory in streptozotocin-induced diabetic mice[J].Brain Res,2016,1644,149-160.
doi: 10.1016/j.brainres.2016.05.013
13 Mandwie M , Karunia J , Niaz A , et al.Metformin treatment attenuates brain inflammation and rescues PACAP/VIP neuropeptide alterations in mice fed a high-fat diet[J].Int J Mol Sci,2021,22(24):13660.
doi: 10.3390/ijms222413660
14 Asgharzadeh F , Barneh F , Fakhraie M , et al.Metformin inhibits polyphosphate-induced hyper-permeability and inflammation[J].Int Immunopharmacol,2021,99,107937.
doi: 10.1016/j.intimp.2021.107937
15 Ismail HF , Didari T , Baeeri M , et al.Metformin attenuates brain injury by inhibiting inflammation and regulating tight junction proteins in septic rats[J].Cell J,2020,22(Suppl 1):S29-S37.
16 Pescador N , Francisco V , Vázquez P , et al.Metformin reduces macrophage HIF1α-dependent proinflammatory signaling to restore brown adipocyte function in vitro[J].Redox Biol,2021,48,102171.
doi: 10.1016/j.redox.2021.102171
17 Xiang X , Zhou L , Lin Z , et al.Metformin regulates macrophage polarization via the Shh signaling pathway to improve pulmonary vascular development in bronchopulmonary dysplasia[J].IUBMB life,2022,74(3):259-271.
doi: 10.1002/iub.2588
18 Katila N , Bhurtel S , Park PH , et al.Activation of AMPK/aPKCζ/CREB pathway by metformin is associated with upregulation of GDNF and dopamine[J].Biochem Pharmacol,2020,180,114193.
doi: 10.1016/j.bcp.2020.114193
19 Ghadernezhad N , Khalaj L , Pazoki-toroudi H , et al.Metformin pretreatment enhanced learning and memory in cerebral forebrain ischaemia: The role of the AMPK/BDNF/P70SK signalling pathway[J].Pharm Biol,2016,54(10):2211-2219.
doi: 10.3109/13880209.2016.1150306
20 Yuan R , Wang Y , Li Q , et al.Metformin reduces neuronal damage and promotes neuroblast proliferation and differentiation in a cerebral ischemia/reperfusion rat model[J].Neuroreport,2019,30(3):232-240.
doi: 10.1097/WNR.0000000000001190
21 Ahmed S , Mahmood Z , Javed A , et al.Effect of metformin on adult hippocampal neurogenesis: Comparison with donepezil and links to cognition[J].J Mol Neurosci,2017,62(1):88-98.
doi: 10.1007/s12031-017-0915-z
22 Sharma S , Nozohouri S , Vaidya B , et al.Repurposing metformin to treat age-related neurodegenerative disorders and ischemic stroke[J].Life Sci,2021,274,119343.
doi: 10.1016/j.lfs.2021.119343
23 UK Prospective Diabetes Study (UKPDS) Group .Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)[J].Lancet,1998,352(9131):854-865.
doi: 10.1016/S0140-6736(98)07037-8
24 Griffin SJ , Leaver JK , Irving GJ .Impact of metformin on cardiovascular disease: A meta-analysis of randomised trials among people with type 2 diabetes[J].Diabetologia,2017,60(9):1620-1629.
doi: 10.1007/s00125-017-4337-9
25 Benn M , Emanuelsson F , Tybjærg-hansen A , et al.Impact of high glucose levels and glucose lowering on risk of ischaemic stroke: A mendelian randomisation study and meta-analysis[J].Diabetologia,2021,64(7):1492-1503.
doi: 10.1007/s00125-021-05436-0
26 Roumie CL , Hung AM , Greevy RA , et al.Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: A cohort study[J].Ann Intern Med,2012,157(9):601-610.
doi: 10.7326/0003-4819-157-9-201211060-00003
27 Holman RR , Paul SK , Bethel MA , et al.10-year follow-up of intensive glucose control in type 2 diabetes[J].N Engl J Med,2008,359(15):1577-1589.
doi: 10.1056/NEJMoa0806470
28 Cryer DR , Nicholas SP , Henry DH , et al.Comparative outcomes study of metformin intervention versus conventional approach the COSMIC approach study[J].Diabetes Care,2005,28(3):539-543.
doi: 10.2337/diacare.28.3.539
29 Kooy A , De JJ , Lehert P , et al.Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus[J].Arch Intern Med,2009,169(6):616-625.
doi: 10.1001/archinternmed.2009.20
30 Gram J , Henriksen JE , Grodum E , et al.Pharmacological treatment of the pathogenetic defects in type 2 diabetes: The randomized multicenter South Danish diabetes study[J].Diabetes Care,2011,34(1):27-33.
doi: 10.2337/dc10-0531
31 王梦莹, 任涛, 吴涛, 等.北方农村地区居民常见慢性非传染性疾病的家系队列研究进展[J].中华流行病学杂志,2018,39(1):4.
32 Glueck DH .Sample size calculations in clinical research[J].Biometrics,2008,64(4):1307-1308.
doi: 10.1111/j.1541-0420.2008.01138_10.x
33 Matsumoto M , Harada S , Iida M , et al.Validity assessment of self-reported medication use for hypertension, diabetes, and dyslipidemia in a pharmacoepidemiologic study by comparison with health insurance claims[J].J Epidemiol,2021,31(9):495-502.
doi: 10.2188/jea.JE20200089
34 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国实用内科杂志,2018,38(4):53.
35 Chen R , Ovbiagele B , Feng W .Diabetes and stroke: Epidemiology, pathophysiology, pharmaceuticals and outcomes[J].Am J Med Sci,2016,351(4):380-386.
doi: 10.1016/j.amjms.2016.01.011
36 Roumie CL , Chipman J , Min JY , et al.Association of treatment with metformin vs sulfonylurea with major adverse cardiovascular events among patients with diabetes and reduced kidney function[J].JAMA,2019,322(12):1167-1177.
doi: 10.1001/jama.2019.13206
37 Douros A , Dell'aniello S , Yu OHY , et al.Sulfonylureas as second line drugs in type 2 diabetes and the risk of cardiovascular and hypoglycaemic events: Population based cohort study[J].BMJ,2018,362,k2693.
38 Chen TH , Li YR , Chen SW , et al.Sodium-glucose cotransporter 2 inhibitor versus metformin as first-line therapy in patients with type 2 diabetes mellitus: A multi-institution database study[J].Cardiovasc Diabetol,2020,19(1):189.
doi: 10.1186/s12933-020-01169-3
39 Sato A , Sunayama J , Okada M , et al.Glioma-initiating cell elimination by metformin activation of FOXO3 via AMPK[J].Stem Cells Transl Med,2012,1(11):811-824.
doi: 10.5966/sctm.2012-0058
40 Chiang MC , Cheng YC , Chen SJ , et al.Metformin activation of AMPK-dependent pathways is neuroprotective in human neural stem cells against amyloid-beta-induced mitochondrial dysfunction[J].Exp Cell Res,2016,347(2):322-331.
doi: 10.1016/j.yexcr.2016.08.013
41 Isoda K , Young JL , Zirlik A , et al.Metformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cells[J].Arterioscler Thromb Vasc Biol,2006,26(3):611-617.
doi: 10.1161/01.ATV.0000201938.78044.75
42 Liu Y , Tang G , Li Y , et al.Metformin attenuates blood-brain barrier disruption in mice following middle cerebral artery occlusion[J].J Neuroinflammation,2014,11,177.
doi: 10.1186/s12974-014-0177-4
43 Campvell JM , Bellman SM , Stephenson MD , et al.Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis[J].Ageing Res Rev,2017,40,31-44.
doi: 10.1016/j.arr.2017.08.003
[1] Xiao-yue ZHANG,Yu-xin LIN,Ying JIANG,Lan-chao ZHANG,Mang-yan DONG,Hai-yi CHI,Hao-yu DONG,Li-jun MA,Zhi-jing LI,Chun CHANG. Mediating effect of self-efficacy on self-management ability and self-management behavior in patients with type 2 diabetes mellitus [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 450-455.
[2] Ruo-tong YANG,Meng-ying WANG,Chun-nan LI,Huan YU,Xiao-wen WANG,Jun-hui WU,Si-yue WANG,Jia-ting WANG,Da-fang CHEN,Tao WU,Yong-hua HU. Interaction between ischemic stroke risk loci identified by genome-wide association studies and sleep habits [J]. Journal of Peking University (Health Sciences), 2022, 54(3): 412-420.
[3] LIU Jie,GUO Chao. A prospective cohort study of the influence of positive/negative effectivity on the mortality risk of the Chinese elderly [J]. Journal of Peking University (Health Sciences), 2022, 54(2): 255-260.
[4] CHEN Ping,LI Ze-ming,GUO Yi,SUN Xin-ying,Edwin B. FISHER. To explore medication adherence of patients with type 2 diabetes mellitus using the latent profile analysis based on the Big Five personality theory [J]. Journal of Peking University (Health Sciences), 2021, 53(3): 530-535.
[5] Ze-ming LI,Min GAO,Xue-ying CHEN,Xin-ying SUN. Relationship between the five-factor model of personality traits and self-management attitude of patients with type 2 diabetes [J]. Journal of Peking University (Health Sciences), 2020, 52(3): 506-513.
[6] Wen-ying MENG,Wan-tong HUANG,Jie ZHANG,Ming-yuan JIAO,Lei JIN,Lei JIN. Relationship between serum vitamin E concentration in first trimester and the risk of developing hypertension disorders complicating pregnancy [J]. Journal of Peking University (Health Sciences), 2020, 52(3): 470-478.
[7] Xun TANG,Du-dan ZHANG,Xiao-fei LIU,Qiu-ping LIU,Yang CAO,Na LI,Shao-ping HUANG,Hui-dong DOU,Pei GAO,Yong-hua HU. Application of the China-PAR stroke risk equations in a rural northern Chinese population [J]. Journal of Peking University (Health Sciences), 2020, 52(3): 444-450.
[8] Zi-chang JIA,Xuan LI,Xiao-gang LI,Xiang-zhu ZENG,Jing-yuan LUAN,Chang-ming WANG,Jin-tao HAN. Mechanical thrombectomy treatment in patients with acute ischemic stroke: a single center study [J]. Journal of Peking University(Health Sciences), 2019, 51(2): 256-259.
[9] Jiang XIE,Fei LI. Association of sleep overlap syndrome with type 2 diabetes in a cross-sectional study [J]. Journal of Peking University(Health Sciences), 2019, 51(2): 252-255.
[10] WANG Xiao-hui， ZHANG Yan， LIU Lin-zhi， SHANG Chen-guang . Effects of metformin and adiponectin on endometrial cancer cells growth [J]. Journal of Peking University(Health Sciences), 2018, 50(5): 767-773.
[11] LIN Hong-bo, CHEN Yi, SHEN Peng, LI Xiao-yong,SI Ya-qin, ZHANG Du-dan, TANG Xun, GAO Pei. Incidence and risk factors of chronic kidney disease in community-based patients with diabetes [J]. Journal of Peking University(Health Sciences), 2018, 50(3): 416-421.
[12] TANG Xun1, ZHANG Du-dan, HE Liu, CAO Yang, WANG Jin-wei, LI Na, HUANG Shao-ping, DOU Hui-dong, GAO Pei， HU Yong-hua. Application of the China-PAR risk prediction model for atherosclerotic cardiovascular disease in a rural northern Chinese population [J]. Journal of Peking University(Health Sciences), 2017, 49(3): 439-445.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd